 |
|
HPV DNA plasmids therapeutic vaccine VGX-3100
A DNA vaccine consisting of plasmids encoding the E6 and E7 genes of human papilloma virus (HPV) subtypes 16 and 18, respectively, with potential immunostimulating and antineoplastic activities. Administered via intramuscular electroporation, HPV DNA plasmids therapeutic vaccine VGX-3100 expresses E6 and E7 proteins, which may elicit a cytotoxic T-lymphocyte (CTL) response against cervical cancer cells expressing E6 and E7 proteins, resulting in tumor cell lysis. HPV type 16 and HPV type 18 are the most common HPV types involved in cervical carcinogenesis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| Code name: | | VGX-3100 | | |
| Previous: | HLA-A1, A2, B35-restricted survivin peptides/Montanide ISA-51 vaccine, HLA-A2, A3-restricted FGF-5 peptides/Montanide ISA-51 vaccine, Hodgkin's antigens-GM-CSF-expressing cell vaccine, HPPH, HPV 16 E7:86-93 peptide vaccine | | Next: | HPV L1 VLP vaccine V504, Hsp27 antisense oligonucleotide OGX-427, Hsp90 antagonist KW-2478, Hsp90 inhibitor AUY922, Hsp90 inhibitor BIIB028 |
|
|
